FDA Approves Treatment for Wider Range of Patients with Heart Failure
The Pharma Data
FEBRUARY 24, 2022
Jardiance is also approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of death and hospitalization in patients with heart failure and low ejection fraction. The FDA granted the approval of Jardiance to Boehringer Ingelheim.
52 
Let's personalize your content